SEOUL - Genexine Inc. has signed a $125m licensing out agreement with Tasgen Bio-Tech Co. Ltd., a subsidiary of China’s Tasly Pharmaceutical Co. Ltd., for the development and commercialization of its protein therapies in China.
Under the agreement, Tasgen will acquire the sales rights in the country to three of Genexine’s protein drugs that are already undergoing or set to start clinical development: GX-H9, a human growth hormone, GX-G6, a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?